Heart disease and obesity weight-loss drug study
Part of Hormones & metabolism clinical trials.
This study tests an investigational weight-loss medicine called Zenagamtide for people who have heart or blood vessel disease and are overweight or obese. The goal is to see if it can reduce heart-related risks compared to a placebo (a pill with no active medicine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a heart attack, a stroke, or narrowing of leg arteries that causes pain when walking or needed an amputation due to poor circulation.
- You are overweight or obese (based on your doctor's measurements).
- If you have type 2 diabetes, your blood sugar medication has been stable for at least 90 days before starting the study.
- You have not had a heart attack, stroke, or heart failure flare-up in the 30 days before starting the study.
- You have not taken any GLP-1 or similar weight-loss or diabetes medications (like Ozempic or Wegovy) before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new once-weekly injection to lower blood sugar levels against a standard daily injection in people with type 2 diabetes who are at high risk for heart problems. It aims to find out if the new medicine is more effective in managing blood sugar and body weight.
This study is testing a new tablet called Zenagamtide to help people with extra body weight lose weight. It's for adults who are not diabetic and haven't used similar weight loss drugs before.
This study tests an investigational medicine called Zenagamtide to see if it helps people with excess body weight lose weight. It is specifically for adults in Asia who do not have diabetes and have not taken certain weight-loss or diabetes medicines before.
This study tests how the timing of your meal and how much water you drink with the medicine affect how your body absorbs a new medicine called Zenagamtide. If you have overweight or obesity, this could help find the best way to take the medicine for maximum effect.
This study tests how well adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from their current weight-loss medication (tirzepatide) to a new medicine called zenagamtide. It may help you understand if this new option is easier on your stomach.
This trial tests a new medicine Zenagamtide to see if it helps people with excess weight lose more weight than Semaglutide, an existing weight loss drug. You may join if you are an adult with overweight or obesity but do not have diabetes.
Hear when a new Cardiovascular Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.